Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer
NCT ID: NCT00035152
Last Updated: 2016-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
444 participants
INTERVENTIONAL
2000-06-30
2004-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study compares treatment with Taxol/carboplatin given every 3 weeks to a schedule where it is given weekly.
The purpose of the study is to determine the most effective and safe schedule for giving these drugs in non small cell lung carcinoma.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Docetaxel Plus Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
NCT00003562
Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
NCT00481078
Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer
NCT00003117
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
NCT00946712
Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
NCT00054392
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Paclitaxel and carboplatin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No prior antineoplastic chemotherapy, hormonal therapy or therapy with biological response modifiers
* No previous irradiation to the only area of measurable disease.
Exclusion Criteria
* Patients who have undergone surgery less than 3 weeks prior to enrollment.
* History of serious cardiac disease not adequately controlled.
* Patients with serious active infections or other serious underlying medical condition.
* Uncontrolled diabetes mellitis.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Genesis Cancer Center
Hot Springs, Arkansas, United States
Little Rock Hematology/Oncology Associates
Little Rock, Arkansas, United States
Highlands Oncology Group
Springdale, Arkansas, United States
Medical Oncology Care Associates
Orange, California, United States
Naval Medical Center
San Diego, California, United States
Danbury Hospital/Praxair Cancer Center
Danbury, Connecticut, United States
Walter Reed Army Hospital
Washington D.C., District of Columbia, United States
Washington VA Medical Center
Washington D.C., District of Columbia, United States
Good Samaritan Medical Center
West Palm Beach, Florida, United States
Wellstar Cobb Hospital
Austell, Georgia, United States
Joliet Oncology/Hematology Associates,Ltd.
Joliet, Illinois, United States
Mid Illinois Hematology and Oncology Associates, Ltd.
Normal, Illinois, United States
West Suburban Center for Cancer Care
River Forest, Illinois, United States
Community Cancer Care, Inc.
Indianapolis, Indiana, United States
Associated Physicians & Surgeons Clinic, LLC
Terre Haute, Indiana, United States
Mercy Cancer Center
Mason City, Iowa, United States
Siouxland Hematology/Oncology Associates
Sioux City, Iowa, United States
Jewish Medical Plaza
Louisville, Kentucky, United States
University of Louisville
Louisville, Kentucky, United States
Louisiana Oncology Associates
Lafayette, Louisiana, United States
Louisiana State University Health Sciences Center
Shreveport, Louisiana, United States
Maine General Medical Center
Waterville, Maine, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Hematology and Oncology Associates of Southern Michigan,P.C
Jackson, Michigan, United States
Hennepin County Medical Center
Minneapolis, Minnesota, United States
Fairview-University Medical Center, University of Minnesota
Minneapolis, Minnesota, United States
Metro Minnesota CCOP
Saint Louis Park, Minnesota, United States
Ellis Fischel Cancer Center
Columbia, Missouri, United States
Creighton University Cancer Center
Omaha, Nebraska, United States
The Center for Cancer and Hematologic Disease
Cherry Hill, New Jersey, United States
Hematology-Oncology of Central New Jersey
Red Bank, New Jersey, United States
Community Medical Center
Toms River, New Jersey, United States
New Mexico Oncology Hematology Consultants
Albuquerque, New Mexico, United States
Advanced Oncology Associates
Armonk, New York, United States
Brooklyn VA
Brooklyn, New York, United States
Maimonides Medical Center
Brooklyn, New York, United States
Clifton Springs Hospital and Clinic
Clifton Springs, New York, United States
Goshen Medical Associates
Goshen, New York, United States
New York Oncology-Hematology,P.C./Capital District Hematology, Oncology Associates
Latham, New York, United States
Hematology/Oncology of Rockland
New York, New York, United States
Upstate New York Cancer R & E
Rochester, New York, United States
Raleigh Hematology Associates, Wake Practice
Cary, North Carolina, United States
Quadrangle Medical Specialists, Southern Oncology Research
Greenville, North Carolina, United States
Mid Dakota Clinic
Bismarck, North Dakota, United States
Columbus CCOP
Columbus, Ohio, United States
Central Pennsylvania Hematology & Medical Oncology Associates, P.C.
Lemoyne, Pennsylvania, United States
Albert Einstein Healthcare Network
Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center/University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, United States
Guthrie Clinic Ltd
Sayre, Pennsylvania, United States
Boston Cancer Group, PLC
Memphis, Tennessee, United States
Don & Sybil Harrington Cancer Center
Amarillo, Texas, United States
Brackenridge Hospital
Austin, Texas, United States
Southwest Regional Cancer Center
Austin, Texas, United States
Southwest Cancer Center
Lubbock, Texas, United States
Northwest Medical Specialties, PLLC
Tacoma, Washington, United States
Madigan Army Medical Center
Tacoma, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BMS TAX/MEN.12
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.